相关实验视频
Updated: Jul 25, 2025

08:49
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
45.8K
三循环滴特类药物选择性地抑制雄激素受体阳性前列腺癌细胞
Inderpal Sekhon1, Guanglin Chen1, Keyara Piri1
1Department of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Molecules (Basel, Switzerland)
|June 28, 2023
概括
新的三环二类药物显示出对抗割抵抗性前列腺癌 (CRPC) 的前景. 这些化合物有效地抑制AR阳性细胞中的雄激素受体 (AR) 活性,为CRPC治疗提供了潜在的新治疗途径.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 雄激素受体 (AR) 信号驱动割抵抗性前列腺癌 (CRPC) 的进展.
- 目前针对连接体结合域 (LBD) 的AR抗剂受到CRPC的抵抗机制的限制.
- ARN终端抗剂提供了一个潜在的替代治疗策略.
研究的目的:
- 探索三环二类作为AR抗剂的结构-活性关系.
- 评估新型丁特类药物对AR阳性前列腺癌细胞的抗增殖潜力.
- 为了确定强效和选择性的AR向化合物用于CRPC治疗.
主要方法:
- 合成和制备基于QW07脚手架的二十种三环四.
- 使用AR阳性 (LNCaP,22Rv1) 和AR无 (PC-3,DU145) 前列腺癌细胞系的抗增殖试验.
- 与恩扎胺和QW07.07对抗迪特尔类药物的功效的比较.
主要成果:
- 在AR阳性LNCaP和22Rv1细胞中,六种合成的三环四类药物表现出比恩扎胺更强的功效.
- 四种迪特尔类药物表现出比恩扎拉胺更强的效果,特别针对22Rv1细胞.
- 衍生物显示增强的功效 (IC50 = 0.27μM) 和选择性超过QW07对AR阳性22Rv1细胞.
结论:
- 三环二类化合物代表了针对CRPC中的AR的一类有前途的化合物.
- 优化的二类衍生物可以克服与当前AR抗剂相关的抵抗机制.
- 这些N端AR抗剂的进一步开发有可能改善CRPC疗法.
关键词:
N-终端域域名是一个N-终端域名.QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07 QW07受体对抗剂 受体对抗剂这是一种二氧化的二氧化.前列腺癌是前列腺癌.更多相关视频
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
891
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
891
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
932
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
932
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
453
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
453
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

